MedTrace Logo

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

NCT00295503 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2020-10-20

Study results available
· View outcomes & findings →

Summary

To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab

Conditions

Interventions

DRUG

bevacizumab

15 mg/kg IV every 3 weeks

DRUG

cisplatin

75 mg/m2 IV every 3 weeks

DRUG

pemetrexed

500 mg/m2 every 3 weeks

Sponsors & Collaborators

  • University of Chicago

    collaborator OTHER

  • Columbia University

    collaborator OTHER

  • Duke University

    collaborator OTHER

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Jonathan E Dowell, MD · University of Texas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2010-06-30
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00295503 on ClinicalTrials.gov